Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

UCB Exercises Tozadenant Option But Asks Biotie To Move It To Phase III

This article was originally published in The Pink Sheet Daily

Executive Summary

Biotie Therapies gets $20 million as UCB exercises its option on the investigational Parkinson's disease therapy tozadenant and asks the Finnish biotech to continue its clinical development of the product into Phase III.

You may also be interested in...



UCB's Keppra Follow-On Briviact Gains FDA Nod For Epileptic Seizures

A next-generation version of levetiracetam, brivaracetam could help UCB recapture some revenue it's losing to generic competition for the mature epilepsy drug.

Biotie Gears Up For New Pivotal Trial Of Tozadenant In Parkinson’s

With the goal of introducing the first adenosine A2a antagonist for Parkinson’s disease in North America and Europe, Biotie plans to start a Phase III study of tozadenant in almost 900 Parkinson’s patients this summer.

Biotie Gears Up For New Pivotal Trial Of Tozadenant In Parkinson’s

With the goal of introducing the first adenosine A2a antagonist for Parkinson’s disease in North America and Europe, Biotie plans to start a Phase III study of tozadenant in almost 900 Parkinson’s patients this summer.

Related Content

Topics

Related Companies

Related Deals

UsernamePublicRestriction

Register

PS075331

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel